UY28821A1 - Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos. - Google Patents
Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.Info
- Publication number
- UY28821A1 UY28821A1 UY28821A UY28821A UY28821A1 UY 28821 A1 UY28821 A1 UY 28821A1 UY 28821 A UY28821 A UY 28821A UY 28821 A UY28821 A UY 28821A UY 28821 A1 UY28821 A1 UY 28821A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formula
- compound
- inhibitor
- piperidin
- bromo
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 229940122598 Tryptase inhibitor Drugs 0.000 abstract 4
- 239000002750 tryptase inhibitor Substances 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 2
- 230000004962 physiological condition Effects 0.000 abstract 2
- XRGUAUFOUNIQRI-UHFFFAOYSA-N [4-[5-(aminomethyl)-2-fluorophenyl]piperidin-1-yl]-(4-bromo-3-methyl-5-propoxythiophen-2-yl)methanone;hydrochloride Chemical compound Cl.BrC1=C(OCCC)SC(C(=O)N2CCC(CC2)C=2C(=CC=C(CN)C=2)F)=C1C XRGUAUFOUNIQRI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuesto que contienen hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona, de fórmula (I) o un profármaco, sal farmacéuticamente aceptable o solvato de dicho compuesto. Composiciones farmacéuticas que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula I, y un vehículo farmacéuticamente aceptable. Se divulgan los usos de un compuesto de fórmula I como un inhibidor de triptasa, y su utilidad para tratar una afección fisiológica, que necesita la mejora de un inhibidor de triptasa. La presente invención se refiere a la preparación de un compuesto de fórmula I. que comprende una cantidad farmacéuticamente eficaz del compuestos de fórmula I, y un vehículo farmacéuticamente aceptable. Se divulgan los usos de un compuesto de fórmula I como un inhibidor de triptasa, y su utilidad para tratar una afeccíón fisiológica, que necesita la mejora de un inhibidor de triptasa. La presente invención también se refiere a la preparación de un compuesto de fórmula I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692704P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28821A1 true UY28821A1 (es) | 2005-10-31 |
Family
ID=34964263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28821A UY28821A1 (es) | 2004-03-26 | 2005-03-23 | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070142435A1 (es) |
| EP (1) | EP1737848A1 (es) |
| JP (1) | JP2007530580A (es) |
| KR (1) | KR20060130682A (es) |
| CN (1) | CN1956978A (es) |
| AR (1) | AR048336A1 (es) |
| AU (1) | AU2005230934A1 (es) |
| BR (1) | BRPI0509245A (es) |
| CA (1) | CA2560649A1 (es) |
| CR (1) | CR8603A (es) |
| DO (1) | DOP2005000039A (es) |
| EC (1) | ECSP066878A (es) |
| IL (1) | IL178031A0 (es) |
| MA (1) | MA28547B1 (es) |
| MX (1) | MXPA06010610A (es) |
| NO (1) | NO20064811L (es) |
| PA (1) | PA8627601A1 (es) |
| PE (1) | PE20060084A1 (es) |
| RU (1) | RU2330034C1 (es) |
| TN (1) | TNSN06278A1 (es) |
| TW (1) | TW200602035A (es) |
| UA (1) | UA83738C2 (es) |
| UY (1) | UY28821A1 (es) |
| WO (1) | WO2005097780A1 (es) |
| ZA (1) | ZA200607752B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
| AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
| WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
| AR065858A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona. |
| WO2008121669A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto |
| ES2469824T3 (es) | 2007-11-21 | 2014-06-20 | Janssen Pharmaceutica N.V. | Espiropiperidinas para su uso como inhibidores de la triptasa |
| WO2009094641A2 (en) * | 2008-01-24 | 2009-07-30 | Dor Biopharma, Inc. | Topically active steroids for use in interstitial pulmonary fibrosis |
| WO2010022196A2 (en) * | 2008-08-22 | 2010-02-25 | Sanofi-Aventis | [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase |
| TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
| CN102574792B (zh) | 2009-09-24 | 2014-07-09 | 赛诺菲-安万特美国有限责任公司 | (4-氟-3-(哌啶-4-基)-苯甲基)-氨基甲酸叔丁酯的合成及其中间体 |
| AU2010333779A1 (en) * | 2009-12-23 | 2012-07-12 | Sanofi | Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors |
| JP2013515724A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類 |
| EP2515851A1 (en) * | 2009-12-23 | 2012-10-31 | Sanofi | Treatment for inflammatory bowel disease |
| BR112012020965A2 (pt) * | 2010-02-24 | 2016-05-03 | Sanofi Sa | tratamento de condições alérgicas dermatológicas |
| MX360706B (es) | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
| UA126574C2 (uk) * | 2017-02-10 | 2022-11-02 | Дженентек, Інк. | Антитіло проти триптази, його композиція та застосування |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| IL152830A0 (en) * | 2000-05-22 | 2003-06-24 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en not_active Ceased
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Withdrawn
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005230934A1 (en) | 2005-10-20 |
| CR8603A (es) | 2007-06-08 |
| TW200602035A (en) | 2006-01-16 |
| US20070142435A1 (en) | 2007-06-21 |
| CA2560649A1 (en) | 2005-10-20 |
| RU2006137717A (ru) | 2008-05-10 |
| IL178031A0 (en) | 2006-12-31 |
| JP2007530580A (ja) | 2007-11-01 |
| ZA200607752B (en) | 2008-05-28 |
| RU2330034C1 (ru) | 2008-07-27 |
| UA83738C2 (en) | 2008-08-11 |
| CN1956978A (zh) | 2007-05-02 |
| KR20060130682A (ko) | 2006-12-19 |
| BRPI0509245A (pt) | 2007-09-11 |
| PE20060084A1 (es) | 2006-03-09 |
| TNSN06278A1 (en) | 2007-12-03 |
| NO20064811L (no) | 2006-10-23 |
| PA8627601A1 (es) | 2006-01-23 |
| WO2005097780A1 (en) | 2005-10-20 |
| MA28547B1 (fr) | 2007-04-03 |
| MXPA06010610A (es) | 2006-12-15 |
| DOP2005000039A (es) | 2005-10-31 |
| EP1737848A1 (en) | 2007-01-03 |
| ECSP066878A (es) | 2006-11-24 |
| AR048336A1 (es) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28821A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos. | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| ECSP055867A (es) | Derivados de pirrolopirimidina | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| ECSP088871A (es) | Derivados de triazolopirazina | |
| CR20110224A (es) | Pirazolopirimidina inhibidor jak compuestos y metodos | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
| NI201200059A (es) | PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS | |
| SV2006002103A (es) | Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a | |
| UA94129C2 (ru) | Соединения для ингибирования митоза | |
| CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
| SE0400284D0 (sv) | Novel compounds | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| EA201071269A1 (ru) | 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина | |
| NI201100093A (es) | 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6. | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| ECSP056193A (es) | Derivados sustituidos del pirrol | |
| UY32852A (es) | [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]-metanonas disustituidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20120418 |